Wauters L, Slaets H, De Paepe K, et al. - Treatment with probiotics (Bacillus coagulants MY01 and Bacillus subtilis MY02, 2·5 × 10'9 colony-forming units per capsule) was identified as efficacious and safe in functional dyspepsia.

• This is a single-center, randomized, double-blind, placebo-controlled pilot trial.

• Higher proportion of clinical responders was recorded among patients assigned to receive probiotics (48%) vs placebo (20%).

• Adult patients (≥ 18 years) with functional dyspepsia (as defined by Rome IV criteria, on proton-pump inhibitors or off proton-pump inhibitors) exhibit potentially beneficial immune and microbial changes.